Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared a post on LinkedIn:
“We’ve been developing ADCs as targeted drugs.
Biology says otherwise.
- Target expression alone poorly predicts benefit
- ADC efficacy emerges from the interaction between tumor cells, TME, payload, linker, and immune biology
- Precision ADCs require multidimensional biomarkers—not better IHC
- Longitudinal biopsies, ctDNA and spatial profiling should become standard in ADC trials
- The next generation of ADCs will be defined as much by patient selection as by molecular engineering.”
Title: Antibody-drug conjugates in precision oncology
Authors: Barbara Pistilli, Raffaele Colombo, Maria Fernanda Mosele, Sarat Chandarlapaty
Other articles featuring Jean-Charles Soria on OncoDaily.